RECRUITING

Integrating Telehealth to Advance Lung Cancer Screening

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this pragmatic trial is to learn if telehealth strategies can increase shared decision-making (SDM) for lung cancer screening (LCS). It will also learn about the equity of these strategies by conducting non-inferiority analysis by race and sex. The main questions it aims to answer are: 1. Does patient outreach using synchronous and asynchronous telehealth strategies increase completion of SDM visits for LCS? 2. Is the effectiveness of these telehealth strategies similar by race and sex? The study uses a Sequential Multiple Assignment Randomized Trial (SMART) design and includes two stages of interventions. The first stage of intervention includes direct patient outreach with an invitation to schedule either a 1) telehealth SDM visit or 2) telehealth or in-person SDM visit. Participants that do not respond to the first stage interventions receive a text message reminder encouraging SDM visit completion with or without digital care coordination.

Official Title

Integrating Telehealth to Advance Lung Cancer Screening

Quick Facts

Study Start:2024-07-09
Study Completion:2027-01-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06638554

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. are aged 50 to 80
  2. 2. have a history of tobacco use indicated by either: Documented 20 pack-year or greater smoking history in their electronic health record (EHR); OR Self-report via structured survey
  3. 3. currently smoke or formerly smoked cigarettes
  4. 4. have no documented history of lung cancer
  5. 5. have no documented history of lung cancer screening in the 24 months prior to study enrollment
  6. 6. have completed at least one primary care visit at Penn Medicine in the 3 years prior to study enrollment.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Katharine Rendle, PhD
CONTACT
215-349-5442
katharine.rendle@pennmedicine.upenn.edu
Hannah Toneff, MSW, MA
CONTACT
267-882-3186
Hannah.Toneff@pennmedicine.upenn.edu

Principal Investigator

Katharine Rendle, PhD
PRINCIPAL_INVESTIGATOR
Abramson Cancer Center

Study Locations (Sites)

University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: Abramson Cancer Center at Penn Medicine

  • Katharine Rendle, PhD, PRINCIPAL_INVESTIGATOR, Abramson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-09
Study Completion Date2027-01-31

Study Record Updates

Study Start Date2024-07-09
Study Completion Date2027-01-31

Terms related to this study

Additional Relevant MeSH Terms

  • Early Detection of Cancer
  • Telemedicine
  • Decision Making